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Background: Although all classes of antihypertensive treatment can successfully reduce morbidity and
mortality of cardiac pathology, prevention of target organ damages is of great importance beyond blood
pressure lowering. Unlike most dihydropyridines, lercanidipine dilates both afferent and the efferent
arterioles of nephrons, so it may provide renoprotective effects, which other CCBs may not have. The
main purpose of this study is to compare the renoprotective effect of lercanidipine and amlodipine
among hypertensive people aged 55 years and older with newly diagnosed hypertension or those who
were treatment-naïve for one month.
Methods: The study is a prospective, open-labelled, randomized, controlled trial to enrol 232 hyper-
tensive patients aged 55 years. Subjects will be randomized into lercanidipine arm (10e20 mg/day) and
amlodipine arm (5e10 mg/day) by 1:1 ratio. The dosage can be up-titrated to 20 mg/day (lercanidipine
group) and 10 mg/day (amlodipine group), respectively, at week 4 or any following visit thereafter.
Efﬁcacy and safety data will be collected at week 4, 12 and 24 by evaluating the blood pressure lowering,
estimated glomerular ﬁltration rate, creatinine clearance, and urine albumin-creatinine ratio.
Conclusions: The reno-protective effects of new generation of CCBs such as lercanidipine administered to
patients with hypertension are not investigated well. After all, this study will bring beneﬁt to older
patients who need drugs with both excellent anti-hypertensive and reno-protective efﬁcacy. And the
results will be provided for future treatment guideline of elder population in Taiwan.
Copyright  2011, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
Open access under CC BY-NC-ND license.LLC.1. Introduction
Hypertension is the most common cardiovascular condition in
the world and is the leading preventable cause of morbidity and
mortality from coronary heart diseases, heart failure, stroke, and
chronic renal failure. Hypertension is highly prevalent in bothGerontology, Taipei Veterans
aipei 11217, Taiwan.
n).
Peng contributed equally to
linical Gerontology & Geriatrics. Pdeveloped and developing countries (more than 30% of adult
populations) and constitutes one of the major cardiovascular risk
factors and accounts for more than 5% of total deaths worldwide.1
The economic impact of hypertension is huge not only because of
blood pressure control but also the treatment of target organ
damages. The kidney is involved in the pathophysiology of hyper-
tension and is damaged by hypertension.2 Renal hypertensive
injury is mainly caused by microcirculatory changes determining
hypoperfusion, glomerular hypertension, and hyperﬁltration.
Approximately 70% of patients with an elevated serum creatinine
have hypertension; and in 26.8% of patients, end-stage renal
disease was caused by hypertension.3,4ublished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
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makes most hypertensive patients to be older adults. Older
hypertensive patients have 3- to 4-fold higher mortality than those
with normal blood pressure. Renin-proﬁling studies have shown
that people younger than 55 years tend to have higher renin levels
relative to people aged 55 years or older. Thus, the treatment with
angiotensin-converting enzyme (ACE) inhibitors/angiotensin-
receptor blockers (ARBs) or b-blockers, which reduce blood pres-
sure at least in part by suppressing the rennin-angiotensin system
at one point or another, are generally more effective in younger
patients. In contrast, calcium channel blockers (CCBs) and diuretics
are better used as ﬁrst-line agents in older patients.5 High blood
pressure will accelerate the decline in glomerular ﬁltration rate
(GFR) in diabetic and nondiabetic kidney disease.6 Although all
classes of antihypertensive drugs can signiﬁcantly reduce the
morbidity and mortality of cardiac pathology, not all antihyper-
tensive drugs are the same in terms of end-organ protection. It is
well known that treatment with ACE inhibitors or ARBs normalizes
systemic blood pressure and glomerular capillary pressure and
counters both glomerulosclerosis and albuminuria in hypertensive
patients. However, renoprotective effect of CCBs in hypertension
treatment is controversial that the African American Study on
Kidney Disease and Hypertension clearly showed the inferiority of
amlodipine in renoprotection than other classes of antihyperten-
sive drugs.7 A newly synthesized dihydropyridine, that is, lercani-
dipine, presents the advantage of vasodilation both in afferent
and efferent arterioles, which exerts a favorable effect in
renoprotection.
A multicenter trial disclosed that lercanidipine not only
provided a remarkable antihypertensive effect but also an addi-
tional improvement in renal function in patients treatedwith either
ACE inhibitor or ARB.8 Creatinine clearance was signiﬁcantly
increased from 41.8 16.0 mL/min to 48.518.0 mL/min after
6-month treatment period.8 Moreover, another study, which
recruited patients aged 60e85 years, reported the antihypertensive
effect and safety of lercanidipine in elderly patients withoutTable 1
Main study subject selection criteria of LEADER study
Inclusion Criteria
C Females or males aged 55 years or older
C Patients who fulﬁll one of the following criteria
C Hypertension without medication treatment within 1 month before the
initiation of study prescription and with blood pressure level of 140/
90 mmHg or higher (ﬁt any one of them) but lower than 180/105 mmHg
(ﬁt both of them) at baseline
C Newly diagnosed or treatment-naïve hypertensives with blood pressure
level of 140/90 mmHg or higher (ﬁt any one of them) but lower than 180/
105 mmHg (ﬁt both of them) at baseline
C Willing and able to provide informed consent
ALT¼ alanine aminotransferase; AST¼ aspartate aminotransferase; eGFR¼ estimated glocausing reﬂex tachycardia.9 In addition, lercanidipine undergoes
extensive hepatic metabolism and processes a gradual and long-
lasting effect that encourages the better compliance with once-
daily regimen and suggests the use in patients with impaired renal
function. On the other hand, other long-acting dihydropyridines,
amlodipine, has been shown to have an unfavorable renoprotective
proﬁle.7 Therefore, the main purpose of this study is to evaluate the
safety, efﬁcacy, and renoprotective effects of lercanidipine
compared with amlodipine in people aged 55 years and older in
Taiwan.
2. Methods
2.1. Objectives
This study aims to compare the renoprotective effect of lerca-
nidipine with amlodipine in hypertensive patients at least 55 years
old, which is evaluated by the change in estimated GFR (eGFR) at
Week 12. Secondary objectives of this study are as follows: (1) the
change in eGFR at Week 24; (2) the change in serum/urine creati-
nine and the estimation of creatinine clearance (eCCr) at Week 12
and 24; (3) the change in microalbuminuria, expressed as the urine
albumin-creatinine ratio at Week 12 and 24; (4) the change in
sitting systolic and diastolic blood pressure by visits; and (5) the
proportion of responding that is deﬁned as systolic blood pressure
reduction at least 10 mmHg at Week 24.
2.2. Study design and treatment plan
This is a prospective, open-labeled, randomized, controlled,
multicenter trial that contains two treatment groups. It is estimated
to recruit 232 hypertensive patients aged 55 years and older. Table 1
lists the main eligibility criteria for all the subjects enrolled in this
study. Eligible patients will be 1:1 randomly assigned to receive
lercanidipine 10 mg/d or amlodipine 5 mg/d treatment. There will
be 116 patients for each treatment group (lercanidipine) in the trialExclusion Criteria (Patients will be excluded from the study for any of the
following reasons)
C Females who are pregnant, breast-feeding, or intent to be pregnant during
study period
C Known secondary, or accelerated, or malignant hypertension within 6
months before enrollment
C Patients with unstable cardiovascular disease, such as myocardial infarc-
tion, unstable angina pectoris, valvular heart disease, arrhythmia, severe
heart failure (New York Heart Association Class IIIeIV), stroke, and so on, or
coronary bypass surgery or any percutaneous coronary intervention within
6 months before enrollment
C Patient with diabetes mellitus according to deﬁnition of American Diabetes
Association
C Patients with chronic kidney disease Stage 4e5 (deﬁned as eGFR level
higher than 30 mL/min/1.73 m2)
C History or presence of malignancy other than nonmelanoma skin cancer
within 5 years before enrollment.
C Patient with urine albumin-creatinine ratio higher than 300 mg/g, ALT and/
or ASTmore than two times the upper limit of normal, total bilirubin higher
than 2.0 mg/dL, serum potassium level higher than 5.5 mmol/L or less than
3.5 mmol/L.
C Known hypersensitivity to the active ingredient or to any of the excipients
of lercanidipine or amlodipine
C Patients on immunosuppressive therapy and active nephrotic syndrome
C Patients who have received any investigational product within 30 days
before enrollment
C History of alcohol or substance abuse
merular ﬁltration rate.
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These patients have to be directly enrolled in the clinical coordi-
nating centers of the study, located in the Center for Geriatrics and
Gerontology of Taipei Veterans General Hospital, Center for Geri-
atrics and Gerontology of Taichung Veterans General Hospital,
Geriatric Medicine Center of Kaohsiung Veterans General Hospital,
Department of Family Medicine, Yuanshan Veterans Hospital, and
Department of Medicine of Kaohsiung Medical University Hospital.
For all participants, the dosage used could be escalated to
20 mg/d of lercanidipine and 10 mg/d of amlodipine at Week 4 or
any following visit thereafter, in those who do not reach the
treatment target based on the best judgment of the investigators. If
the blood pressure still cannot be controlled well at Week 12
postdose escalation, investigator may discontinue the study treat-
ment earlier for add-on or switching to other antihypertensive
agents. Efﬁcacy and safety data will be collected at Week 4, 12, and
24. Data about safety, efﬁcacy, physical, and biochemical parame-
ters will also be collected individually for the deﬁned time points
(Fig. 1).
The study protocol will be approved by the Institutional Review
Board (IRB) of all participating hospitals. The principal investiga-
tors’ agreements were provided to the IRB or ethics committeewith
all appropriatematerial, including the informed consent document.
This trial would not be initiated until appropriate IRB approvals of
the protocol, the informed consent documents, the receiving con-
ﬁrming of investigator(s), those received copies of the submitted
documents, and the approval letter had been exactly organized.
Appropriate reports on the progress of this study by the principal
investigator will be made to the IRB in a timely manner in accor-
dance with applicable government regulations and in agreement
with policy established by each center.
Other treatment may be continued during the trial and when-
ever possible at ﬁxed dose. This should be noted in the case report
form. Subjects were prohibited treatments of other antihyperten-
sive and investigational drug during the study period. Subjects’
condition in this trial would be evaluated according to the
endpoints of change in laboratory results, adverse events (AEs), and
serious AEs (SAEs).
The aforementioned “change in laboratory results” contains
laboratory results, such as eGFR, eCcr, serum/urine creatinine, and
urine albumin-creatinine ratio thereof. Here, the occurrence of AEs
were determined by any untoward medical occurrence in a patient
or clinical investigation subject administered a pharmaceutical
product and which does not necessarily have to possess a causal
relationship with this treatment. SAEs were any experience thatTrea
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Fig. 1. Study design ofsuggests a signiﬁcation hazard, contraindication, serious side effect,
or precaution. AEs were coded with Medical Dictionary for Regu-
latory Activities and a summary frequency table of AEs was
provided. The severity and relationship to study medication of AEs
was summarized as well. The brief summary about SAEs was also
described. SAEs will be listed and described in tables. Meanwhile,
the record of the efﬁcacy/safety data and the vital signs will be
collected in this study.
2.3. The study population
All participants need to be newly diagnosed with hypertension
or treatment naïve within 1 month before the initiation of study
and with their blood pressure level of 140/90 mmHg or higher (ﬁt
any one of them) but lower than 180/105 mmHg (ﬁt both of them)
at baseline were diagnosed. For all participants, the therapeutic
goal of blood pressure control is stratiﬁed by their age: (1) age of
55e69 years at systolic blood pressure higher than 140 mmHg and
diastolic blood pressure lower than 90 mmHg; (2) age of 70e79
years at systolic blood pressure higher than 150 mmHg and dia-
stolic blood pressure lower than 90 mmHg; and (3) age 80 years or
older at systolic blood pressure lower than 160 mmHg and diastolic
blood pressure lower than 90 mmHg.10
Patients will be excluded from the study if they are pregnant
female, with known secondary hypertension, or with unstable
cardiovascular diseases. In addition, those who were diagnosed
with diabetes mellitus, chronic kidney disease Stage 4e5, malig-
nancies, or serious abnormality in urinary were also excluded. At
last, people who were alcohol/drug abusers or allergic to any
excipients of lercanidipine or amlodipine were excluded. The
subjective study population design described above can be
understood clearly by the inclusion/exclusion criteria as shown in
Table 1.
2.4. Statistical analysis plan
This study is designed to demonstrate that the study drug is
superior to active drug, and the statistical power had to achieve 80%
under 0.05 conﬁdence level. At least 232 patients will be enrolled in
a 1:1 ratio to therapy of lercanidipine (116 patients) or amlodipine
(116 patients). The sample size estimation assumes that the true
mean difference between a test drug and an active control drug is
4 mL/min. Assumed mean change of GFR from baseline to Month 3
in amlodipine is 0.16 mL/min/1.73 m2 (standard deviation¼ 13.6)
and mean change of GFR from baseline to Month 3 in ramipril istment period 
Wk 
12
Wk 
24
the LEADER study.
Table 3
Flow chart of LEADER study
Visit number Screening Baseline Treatment
1 2 3 4 5/ET
Time of visit (wk d) 4, 0 0 4 4 12 1 24 1
Informed consent X
Inclusion/exclusion criteria X X
Randomization X
Demographics X
Medical history X
Physical examinationa X X X X X
Blood pressure/heart rate X X X X X
Biochemistry
ALT X X X
AST X X X
Total bilirubin X X
Serum creatinine X Xb X X X
BUN X Xb X X X
Glucose X
Sodium X Xb X X X
Potassium X Xb X X X
Calcium X Xb X X X
Urinalysis
b-hCGc X
Urine creatinine X Xb X X
Spot urine albumin X Xb X X
Antihypertensive therapy X X X X
Drug accountability X X X
Prior/concomitant medicationd X X X X X
Adverse events X X X X
a Body height will be only measured at screening visit.
b Urine pregnancy test will only be conducted in female of childbearing potential.
c These tests could be omitted if the screening visit is conducted within 7 days.
d The record of concomitant medication should be traced back to 30 days before
the commencement of observational prescription.
ALT¼ alanine aminotransferase;AST¼ aspartate aminotransferase;b-hCG¼ b-human
chorionic gonadotropin; BUN¼ blood urea nitrogen; ET¼ earlier termination (the
ﬁnal visit could be conducted when subject discontinues from the study earlier).
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sample t test will have 80% power to show a statistical difference
between arms.
The primary endpoint is the change in eGFR at Week 12.
Descriptive statistical analysis will be provided and the comparison
between arms will be tested by using two-sample t test. The
secondary endpoint are the change in eGFR, serum/urine creatinine,
and eCCr; microalbuminuria and sitting blood pressure will
be summarized at 4, 12, and 24 weeks after initiation of study
prescription. In addition, the difference between treatment groups
will be analyzed by using t test or analysis of variance. For the
proportion, analyses will be summarized as frequency table and c2
test or Fisher’s exact test will be used to compare between arms. For
the safety analysis, the summary results of laboratory at the baseline
and the end of study visit, and the change from baseline to end of
study visit will be summarized by descriptive statistics and paired
t test. The AEs will be summarized by frequency tables. In Table 2,
the calculated sample sizes within each different armwith different
d (milliliter/min) from the aforementioned equation are listed.
2.5. Data collection and study traits
The data collected from laboratorial examinations and the
records of vital signs are executed step by step as the chart shown
as Table 3. Laboratory tests are implemented according to the
protocols, such as pregnancy tests, biochemical examinations, and
the urology testing. However, pregnancy test will be only con-
ducted in female subjects of childbearing potential. The investi-
gator should counsel the patient and inform the risks of continuing
with the pregnancy and the possible effects on the fetus. All female
patients should be instructed to immediately inform the investi-
gator if she becomes pregnant during study period. Blood sample
will be drawn for biochemistry examinations in all patients at every
visit. At each visit, both eGFR and eCCr will be determined from the
serum creatinine using the biostatistical formula.11 In the begin-
ning, the value of eGFR will be calculated by Modiﬁcation of Diet in
Renal Disease formula or by Cockcroft-Gault formula,12and the last
parameter in the aforesaid equations will be chosen from one of
the numbers: 1.233 (if Chinese) and 1.21 (if Black).13 During the
screening period, patients with fasting glucose level higher than
126 mg/dL on two different occasions or random glucose level
higher than 200 mg/dL should be excluded. Urine sample will be
collected for routine urinalysis, such as urine creatinine and spot
urine albumin, will be conducted at screening, baseline, and at Visit
4 and 5. The microalbuminuria will be determined by spot urine
albumin and be presented by the albumin-creatinine ratio.
3. Discussion
CCB and thiazide diuretics both are the recommended starting
antihypertensive agents among patients aged older than 55 years
by the British Hypertension Society. However, geriatricians do
worry about the adverse effect of diuretics in hypertension treat-
ment for older patients because of the postural hypotension and
increased tendency to fall. This trial is designed to compare the
renoprotective effects of different CCBs whose effects are much
different toward the efferent arterioles, and this research especiallyTable 2
Endpoint-series sample size of arms with different d (milliliter/min)
Per arm d(mL/min)
2 1.5 1 0.5 0
13 261 167 116 85 65
The number of the probable sample size in each treatment group was 167.focused on the observation of the difference between lercanidipine
and another CCB, amlodipine. It is well known that treatment with
ACE inhibitors/ARBs can be administered to hypertensive patients
and these two categories of medicines will present protective effect
upon the renal function, especially the glomerular microcircularory
system. Most CCBs dilate afferent but not efferent arterioles,
which might be associated with worsening of glomerular injury.14
Patients treated with all those aforesaid antihypertensive agents
can signiﬁcantly reduce the morbidity and mortality of cardiac
pathology, but only limited results were obtained in patients with
end-stage renal disease.
Experts in the ﬁeld of cardiovascular disease have noticed that
those who used antihypertensive drugs somehow have disadvan-
tages for those with unhealthy renal function. Compared with the
old generations of CCBs, which dilate afferent but not efferent
arterioles, the new generation of CCBs can dilate not only the
afferent but also the efferent arterioles, so physicians have started
to ﬁnd out the antihypertensive drugs those offer better neph-
roprotection.9,14 Most researchers try to sieve the study targets
from the third generation of the antihypertensive drugs of CCBs.
But whether CCBs will prevent the glomerular microcirculation
from damage caused by huge difference between afferent and
efferent arterioles or not is studied much little in this ﬁeld. Newly
synthesized dihydropyridine, such as lercanidipine, present the
advantages of vasodilation both in afferent and efferent arterioles.
Among various new antihypertensive CCBs, lercanidipine reveals to
have less adverse side effect, especially peripheral edema toward
elder patients.15,16 As human generation grows older all around the
world, it is important to ﬁnd out a regimen, which can not only
C.-K. Liang et al. / Journal of Clinical Gerontology & Geriatrics 2 (2011) 88e9292decrease blood pressure but also be able to protect the patients’
renal functions meanwhile.
From the abovementioned description, a more effective reno-
protection in the third generation of CCBs prescribed to older
generations could be found on hypertensive patients those who
had received antihypertensive drugs before, and the renoprotection
effects will be evaluated more quantitatively in this study. Thus, to
approve that lercanidipine not only provided a high antihyper-
tensive effect but also an additional improvement within renal
function among elderly patients, this studywill investigate both the
antihypertensive and renoprotective efﬁcacy of lercanidipine
within hypertensive patients those who are at least 55 years old in
Taiwan. Amlodipine, an antihypertensive drug in habitually treat-
ment, will be prescribed to the other set of subjects as a compared
group to ﬁgure out the effect of lercanidipine quantitatively.
The renoprotective effects of new generation of CCBs, such as
lercanidipine, administered to patients with hypertension are not
investigated well; yet, this trial will try to study this protective
phenomenon on the elderly patients who are diagnosed with
hypertension and administered lercanidipine as regimen. After all,
this study will bring beneﬁt to older patients who need drugs with
both excellent antihypertensive and renoprotective efﬁcacy. And
the results will be provided for future treatment guideline of
elderly population in Taiwan.
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